{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T10:11:30Z","timestamp":1760523090843},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2013,8,16]],"date-time":"2013-08-16T00:00:00Z","timestamp":1376611200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2013,8,16]],"date-time":"2013-08-16T00:00:00Z","timestamp":1376611200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Gene Ther"],"published-print":{"date-parts":[[2013,9]]},"DOI":"10.1038\/cgt.2013.48","type":"journal-article","created":{"date-parts":[[2013,8,16]],"date-time":"2013-08-16T10:15:39Z","timestamp":1376648139000},"page":"514-520","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Targeted expression of human folylpolyglutamate synthase for selective enhancement of methotrexate chemotherapy in osteosarcoma cells"],"prefix":"10.1038","volume":"20","author":[{"given":"K","family":"Bienemann","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M S","family":"Staege","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S J","family":"Howe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Sena-Esteves","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H","family":"Hanenberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C M","family":"Kramm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,8,16]]},"reference":[{"key":"BFcgt201348_CR1","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1200\/JCO.2002.20.3.776","volume":"20","author":"SS Bielack","year":"2002","unstructured":"Bielack SS, Kempf-Bielack B, Delling G, Exner GU, Flege S, Helmke K et al. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol 2002; 20: 776\u2013790.","journal-title":"J Clin Oncol"},{"key":"BFcgt201348_CR2","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1200\/JCO.2005.04.063","volume":"23","author":"B Kempf-Bielack","year":"2005","unstructured":"Kempf-Bielack B, Bielack SS, J\u00fcrgens H, Branscheid D, Berdel WE, Exner GU et al. Osteosarcoma relapse after combined modality therapy: an analysis of unselected patients in the Cooperative Osteosarcoma Study Group (COSS). J Clin Oncol 2005; 23: 559\u2013568.","journal-title":"J Clin Oncol"},{"key":"BFcgt201348_CR3","doi-asserted-by":"publisher","first-page":"2127","DOI":"10.1002\/(SICI)1097-0142(19961115)78:10<2127::AID-CNCR13>3.0.CO;2-0","volume":"78","author":"N Delepine","year":"1996","unstructured":"Delepine N, Delepine G, Bacci G, Rosen G, Desbois JC . Influence of methotrexate dose intensity on outcome of patients with high grade osteogenic osteosarcoma. Analysis of the literature. Cancer 1996; 78: 2127\u20132135.","journal-title":"Cancer"},{"key":"BFcgt201348_CR4","first-page":"621","volume":"5","author":"W Guo","year":"1999","unstructured":"Guo W, Healey JH, Meyers PA, Ladanyi M, Huvos AG, Bertino JR et al. Mechanisms of methotrexate resistance in osteosarcoma. Clin Cancer Res 1999; 5: 621\u2013627.","journal-title":"Clin Cancer Res"},{"key":"BFcgt201348_CR5","doi-asserted-by":"publisher","first-page":"1958","DOI":"10.1002\/cncr.11741","volume":"98","author":"I Ifergan","year":"2003","unstructured":"Ifergan I, Meller I, Issakov J, Assaraf YG . Reduced folate carrier protein expression in osteosarcoma: implications for the prediction of tumor chemosensitivity. Cancer 2003; 98: 1958\u20131966.","journal-title":"Cancer"},{"key":"BFcgt201348_CR6","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1172\/JCI22477","volume":"115","author":"L Kager","year":"2005","unstructured":"Kager L, Cheok M, Yang W, Zaza G, Cheng Q, Panetta JC et al. Folate pathway gene expression differs in subtypes of acute lymphoblastic leukemia and influences methotrexate pharmacodynamics. J Clin Invest 2005; 115: 110\u2013117.","journal-title":"J Clin Invest"},{"key":"BFcgt201348_CR7","doi-asserted-by":"publisher","first-page":"4362","DOI":"10.1182\/blood-2008-08-173799","volume":"113","author":"M Stark","year":"2009","unstructured":"Stark M, Wichman C, Avivi I, Assaraf YG . Aberrant splicing of folylpolyglutamate synthetase as a novel mechanism of antifolate resistance in leukemia. Blood 2009; 113: 4362\u20134369.","journal-title":"Blood"},{"key":"BFcgt201348_CR8","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/s10555-007-9049-z","volume":"26","author":"YG Assaraf","year":"2007","unstructured":"Assaraf YG . Molecular basis of antifolate resistance. Cancer Metastasis Rev 2007; 26: 153\u2013181.","journal-title":"Cancer Metastasis Rev"},{"key":"BFcgt201348_CR9","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1093\/jnci\/91.14.1233","volume":"91","author":"M Aghi","year":"1999","unstructured":"Aghi M, Kramm CM, Breakefield XO . Folylpolyglutamyl synthetase gene transfer and glioma antifolate sensitivity in culture and in vivo. J Natl Cancer Inst 1999; 91: 1233\u20131241.","journal-title":"J Natl Cancer Inst"},{"key":"BFcgt201348_CR10","doi-asserted-by":"publisher","first-page":"2909","DOI":"10.1158\/1535-7163.MCT-07-0449","volume":"6","author":"RC Cho","year":"2007","unstructured":"Cho RC, Cole PD, Sohn KJ, Gaisano G, Croxford R, Kamen BA et al. Effects of folate and folylpolyglutamyl synthase modulation on chemosensitivity of breast cancer cells. Mol Cancer Ther 2007; 6: 2909\u20132920.","journal-title":"Mol Cancer Ther"},{"key":"BFcgt201348_CR11","first-page":"4614","volume":"56","author":"SC Ko","year":"1996","unstructured":"Ko SC, Cheon J, Kao C, Gotoh A, Shirakawa T, Sikes RA et al. Osteocalcin promoter-based toxic gene therapy for the treatment of osteosarcoma in experimental models. Cancer Res 1996; 56: 4614\u20134619.","journal-title":"Cancer Res"},{"key":"BFcgt201348_CR12","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1128\/AAC.12.1.11","volume":"12","author":"A Billiau","year":"1977","unstructured":"Billiau A, Edy VG, Heremans H, Van Damme J, Desmyter J, Georgiades JA et al. Human interferon: mass production in a newly established cell line, MG-63. Antimicrob Agents Chemother 1977; 12: 11\u201315.","journal-title":"Antimicrob Agents Chemother"},{"issue":"Suppl. 1","key":"BFcgt201348_CR13","doi-asserted-by":"publisher","first-page":"A52","DOI":"10.1007\/BF02572172","volume":"121","author":"C Mengede","year":"1995","unstructured":"Mengede C, Vukovic V, Gl\u00fcsenkamp KH, J\u00e4hde E, Rajewsky MP . Development of acid-labile immunoconjugates for tumor-specific activation of cytotoxins. J Cancer Res Clin Oncol 1995; 121 (Suppl. 1): A52.","journal-title":"J Cancer Res Clin Oncol"},{"key":"BFcgt201348_CR14","doi-asserted-by":"crossref","first-page":"3362","DOI":"10.1016\/S0021-9258(18)34781-1","volume":"257","author":"RJ Majeska","year":"1982","unstructured":"Majeska RJ, Rodan GA . The effect of 1,25(OH)2D3 on alkaline phosphatase in osteoblastic osteosarcoma cells. J Biol Chem 1982; 257: 3362\u20133365.","journal-title":"J Biol Chem"},{"key":"BFcgt201348_CR15","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1084\/jem.97.5.695","volume":"97","author":"WF Scherer","year":"1953","unstructured":"Scherer WF, Syverton JT, Gey GO . Studies on the propagation in vitro of poliomyelitis viruses. IV. Viral multiplication in a stable strain of human malignant epithelial cells (strain HeLa) derived from an epidermoid carcinoma of the cervix. J Exp Med 1953; 97: 695\u2013710.","journal-title":"J Exp Med"},{"key":"BFcgt201348_CR16","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1126\/science.2981116","volume":"227","author":"DC Rio","year":"1985","unstructured":"Rio DC, Clark SG, Tjian R . A mammalian host-vector system that regulates expression and amplification of transfected genes by temperature induction. Science 1985; 227: 23\u201328.","journal-title":"Science"},{"key":"BFcgt201348_CR17","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1007\/s11060-004-6046-8","volume":"70","author":"S Steffens","year":"2004","unstructured":"Steffens S, Tebbets J, Kramm CM, Lindemann D, Flake A, Sena-Esteves M . Transduction of human glial and neuronal tumor cells with different lentivirus vector pseudotypes. J Neurooncol 2004; 70: 281\u2013288.","journal-title":"J Neurooncol"},{"key":"BFcgt201348_CR18","first-page":"85","volume":"891","author":"SJ Howe","year":"2012","unstructured":"Howe SJ, Chandrashekran A . Vector systems for prenatal gene therapy: principles of retrovirus vector design and production. Methods Mol Biol 2012; 891: 85\u2013107.","journal-title":"Methods Mol Biol"},{"key":"BFcgt201348_CR19","first-page":"359","volume":"4","author":"J Cheon","year":"1997","unstructured":"Cheon J, Ko SC, Gardner TA, Shirakawa T, Gotoh A, Kao C et al. Chemogene therapy: osteocalcin promoter-based suicide gene therapy in combination with methotrexate in a murine osteosarcoma model. Cancer Gene Ther 1997; 4: 359\u2013365.","journal-title":"Cancer Gene Ther"},{"key":"BFcgt201348_CR20","first-page":"274","volume":"5","author":"T Shirakawa","year":"1998","unstructured":"Shirakawa T, Ko SC, Gardner TA, Cheon J, Miyamoto T, Gotoh A et al. In vivo suppression of osteosarcoma pulmonary metastasis with intravenous osteocalcin promoter-based toxic gene therapy. Cancer Gene Ther 1998; 5: 274\u2013280.","journal-title":"Cancer Gene Ther"},{"key":"BFcgt201348_CR21","first-page":"1591","volume":"12","author":"R Benjamin","year":"2001","unstructured":"Benjamin R, Helman L, Meyers P, Reaman G . A phase I\/II dose escalation and activity study of intravenous injections of OCaP1 for subjects with refractory osteosarcoma metastatic to lung. Hum Gene Ther 2001; 12: 1591\u20131593.","journal-title":"Hum Gene Ther"},{"key":"BFcgt201348_CR22","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1089\/10915360050138620","volume":"4","author":"T Shirakawa","year":"2000","unstructured":"Shirakawa T, Gotoh A, Wada Y, Kamidono S, Ko SC, Kao C et al. Tissue-specific promoters in gene therapy for the treatment of prostate cancer. Mol Urol 2000; 4: 73\u201382.","journal-title":"Mol Urol"},{"key":"BFcgt201348_CR23","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1089\/10430340360535788","volume":"14","author":"H Kubo","year":"2003","unstructured":"Kubo H, Gardner TA, Wada Y, Koeneman KS, Gotoh A, Yang L et al. Phase I dose escalation clinical trial of adenovirus vector carrying osteocalcin promoter-driven herpes simplex virus thymidine kinase in localized and metastatic hormone-refractory prostate cancer. Hum Gene Ther 2003; 14: 227\u2013241.","journal-title":"Hum Gene Ther"},{"key":"BFcgt201348_CR24","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1126\/science.2588000","volume":"246","author":"NA Morrison","year":"1989","unstructured":"Morrison NA, Shine J, Fragonas JC, Verkest V, McMenemy ML, Eisman JA . 1,25-dihydroxyvitamin D-responsive element and glucocorticoid repression in the osteocalcin gene. Science 1989; 246: 1158\u20131161.","journal-title":"Science"},{"key":"BFcgt201348_CR25","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1073\/pnas.86.4.1143","volume":"86","author":"J Lian","year":"1989","unstructured":"Lian J, Stewart C, Puchacz E, Mackowiak S, Shalhoub V, Collart D et al. Structure of the rat osteocalcin gene and regulation of vitamin D-dependent expression. Proc Natl Acad Sci USA 1989; 86: 1143\u20131147.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFcgt201348_CR26","doi-asserted-by":"publisher","first-page":"15","DOI":"10.3109\/03008209609029170","volume":"35","author":"JB Lian","year":"1996","unstructured":"Lian JB, Stein GS, Stein JL, Van Wijnen A, McCabe L, Banerjee C et al. The osteocalcin gene promoter provides a molecular blueprint for regulatory mechanisms controlling bone tissue formation: role of transcription factors involved in development. Connect Tissue Res 1996; 35: 15\u201321.","journal-title":"Connect Tissue Res"},{"key":"BFcgt201348_CR27","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/0167-4781(95)00091-T","volume":"1263","author":"NC Arbour","year":"1995","unstructured":"Arbour NC, Darwish HM, DeLuca HF . Transcriptional control of the osteocalcin gene by 1,25-dihydroxyvitamin D-2 and its 24-epimer in rat osteosarcoma cells. Biochim Biophys Acta 1995; 1263: 147\u2013153.","journal-title":"Biochim Biophys Acta"},{"key":"BFcgt201348_CR28","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1203\/01.PDR.0000132666.23103.EF","volume":"56","author":"S Steffens","year":"2004","unstructured":"Steffens S, Sandquist A, Frank S, Fischer U, Lex C, Rainov NG et al. A neuroblastoma-selective suicide gene therapy approach using the tyrosine hydroxylase promoter. Pediatr Res 2004; 56: 268\u2013277.","journal-title":"Pediatr Res"},{"key":"BFcgt201348_CR29","doi-asserted-by":"publisher","first-page":"2389","DOI":"10.1089\/104303400750038499","volume":"11","author":"NG Rainov","year":"2000","unstructured":"Rainov NG . A phase III clinical evaluation of herpes simplex virus type 1 thymidine kinase and ganciclovir gene therapy as an adjuvant to surgical resection and radiation in adults with previously untreated glioblastoma multiforme. Hum Gene Ther 2000; 11: 2389\u20132401.","journal-title":"Hum Gene Ther"},{"key":"BFcgt201348_CR30","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1006\/bbrc.1996.1573","volume":"227","author":"G Zhang","year":"1996","unstructured":"Zhang G, Gurtu V, Kain SR . An enhanced green fluorescent protein allows sensitive detection of gene transfer in mammalian cells. Biochem Biophys Res Commun 1996; 227: 707\u2013711.","journal-title":"Biochem Biophys Res Commun"},{"key":"BFcgt201348_CR31","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1159\/000468766","volume":"44","author":"SK Jang","year":"1990","unstructured":"Jang SK, Pestova TV, Hellen CU, Witherell GW, Wimmer E . Cap-independent translation of picornavirus RNAs: structure and function of the internal ribosomal entry site. Enzyme 1990; 44: 292\u2013309.","journal-title":"Enzyme"},{"key":"BFcgt201348_CR32","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1006\/bbrc.1996.1795","volume":"229","author":"V Gurtu","year":"1996","unstructured":"Gurtu V, Yan G, Zhang G . IRES bicistronic expression vectors for efficient creation of stable mammalian cell lines. Biochem Biophys Res Commun 1996; 229: 295\u2013298.","journal-title":"Biochem Biophys Res Commun"}],"container-title":["Cancer Gene Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/cgt201348.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/cgt201348","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/cgt201348.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,22]],"date-time":"2022-03-22T12:09:15Z","timestamp":1647950955000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/cgt201348"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,8,16]]},"references-count":32,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2013,9]]}},"alternative-id":["BFcgt201348"],"URL":"https:\/\/doi.org\/10.1038\/cgt.2013.48","relation":{},"ISSN":["0929-1903","1476-5500"],"issn-type":[{"value":"0929-1903","type":"print"},{"value":"1476-5500","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,8,16]]},"assertion":[{"value":"10 May 2013","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 June 2013","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 August 2013","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}